Edition:
United States

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

1.14USD
23 Feb 2018
Change (% chg)

$0.05 (+4.59%)
Prev Close
$1.09
Open
$1.10
Day's High
$1.15
Day's Low
$1.10
Volume
80,508
Avg. Vol
54,700
52-wk High
$3.88
52-wk Low
$0.95

Chart for

About

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to... (more)

Overall

Beta: 0.18
Market Cap(Mil.): $12.28
Shares Outstanding(Mil.): 10.77
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.96 16.59
EPS (TTM): -- -- --
ROI: -- 14.08 35.07
ROE: -- 15.71 17.79

BRIEF-683 Capital Management Reports 21.8 Pct Stake In Onconova Therapeutics

* 683 CAPITAL MANAGEMENT LLC REPORTS 21.8 PERCENT STAKE IN ONCONOVA THERAPEUTICS INC AS OF FEB 8 - SEC FILING

Feb 16 2018

BRIEF-Onconova Says Moving Forward With Pivotal Late-Stage Trial

* ONCONOVA MOVING FORWARD WITH PHASE 3 INSPIRE PIVOTAL TRIAL WITH INCREASED SAMPLE SIZE FOLLOWING PROMISING INTERIM ANALYSIS

Jan 17 2018

BRIEF-Onconova Therapeutics Says Entered Into Cooperative Research And Development Agreement With NCI

* ONCONOVA THERAPEUTICS SAYS ENTERED INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH NATIONAL CANCER INSTITUTE

Jan 04 2018

BRIEF-Onconova Therapeutics Announces License And Collaborative Development Agreement With Hanx Biopharma

* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AND COLLABORATIVE DEVELOPMENT AGREEMENT WITH HANX BIOPHARMACEUTICALS FOR ON 123300, A DUAL INHIBITOR OF CDK4/6 + ARK5

Dec 19 2017

BRIEF-Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln

* Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing‍​ Source text: (http://bit.ly/2AiGwl1) Further company coverage:

Nov 20 2017

BRIEF-Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor

* Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor at 2017 American Association Of Pharmaceutical Scientists annual meeting Source text for Eikon: Further company coverage:

Nov 16 2017

BRIEF-Onconova Therapeutics prices public offering

* Onconova Therapeutics announces pricing of public offering of common stock

Nov 10 2017

BRIEF-Onconova Therapeutics reports Q3 revenue $100,000

* Onconova Therapeutics, Inc. reports business highlights and third quarter 2017 financial results

Nov 09 2017

BRIEF-Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics

* Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates

Sep 21 2017

Competitors

Earnings vs. Estimates